Merck, 203811-10UG, Bryostatin 1

General description
A macrocyclic lactone that exhibits anti-tumor properties. Potently activates protein kinase C and exhibits high binding affinity (Ki = 1.35 nM). Effectively translocates protein kinase C (PKC) isozymes α, β, and ε and induces a biphasic, concentration-dependent, down-regulation of PKC δ. Reported to compete with phorbol esters in binding to PKC. Stimulates protein kinase D (PKD) activity in a biphasic, PKC-dependent manner in intact cells. Also activates Ras in Jurkat T cells and in rat2 cells.
A macrocyclic lactone with antitumor properties. Potently activates protein kinase C and exhibits a high binding affinity (Ki = 1.35 nM). Effectively translocates and down-regulates PKC isozymes α, δ, and ε. Induces a biphasic activation of PKD through a PKC-dependent pathway in intact cells. Also shown to activate Ras in Jurkat T cells and in rat2 cells.
Biochem/physiol Actions
Cell permeable: no
Primary Target
Protein kinase C
Product does not compete with ATP.
Reversible: no
Target Ki: 1.35 nM for protein kinase C
Preparation Note
Following reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Clamp, A., and Jayson, G. 2002. Anticancer Drugs13, 673.
Lorenzo, P.S., et al. 1999. Cancer Res.59, 6137.
Wang, Q.J., et al. 1999. J. Biol. Chem.274, 37233.
Wender, P.A., et al. 1998. Proc. Natl. Acad. Sci. USA95, 6624.
Matthews, S.A., et al. 1997. J. Biol. Chem.272, 20245.
Szallasi, Z., et al. 1994. Mol. Pharmacol.46, 840.
Berkow, R.L., and Kratt, A.S. 1985. Biochem. Biophys. Res. Commun.3, 1109.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)